GSK is on the hunt for deals in China after the UK drugmaker rebuilt a “very strong” relationship with the government and local companies since a corruption scandal a decade ago.Chief commercial officer Luke Miels told the Financial Times that the company was working on further deals with Chinese companies after it signed a licensing agreement in October worth up to $1.5bn for a cancer drug developed by Hansoh Pharma.
葛兰素史克(GSK)正在manbetx3.0 寻觅交易。自10年前爆出腐败丑闻以来，这家英国制药商与政府和当地企业重建了“非常牢固”的关系。
您已阅读11%（482字），剩余89%（3770字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。